Peraso (PRSO) 10-Q 15 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	Apr. 30, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Trading Symbol	MOSY
Entity Registrant Name	MoSys, Inc.
Entity Central Index Key	0000890394
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		43,139,146

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 4,765	$ 7,104
Short-term investments	1,564
Accounts receivable	2,171	1,622
Inventories	902	1,148
Prepaid expenses and other	1,171	923
Total current assets	10,573	10,797
Property and equipment, net	255	279
Goodwill	420	420
Right-of-use lease asset	297
Other	260	260
Total assets	11,805	11,756
Current liabilities
Accounts payable	215	236
Deferred revenue	269	273
Short-term lease liability	197
Accrued expenses and other	1,098	1,402
Total current liabilities	1,779	1,911
Long-term lease liability	115	17
Convertible notes payable	2,749	2,671
Total liabilities	4,643	4,599
Commitments and contingencies (Note 4)
Stockholders' equity
Preferred stock, $0.01 par value; 20,000 shares authorized; none issued and Outstanding
Common stock, $0.001 par value; 120,000 shares authorized; 43,139 shares and 42,967 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively	43	43
Additional paid-incapital	242,976	242,981
Accumulated deficit	(235,857)	(235,867)
Total stockholders' equity	7,162	7,157
Total liabilities and stockholders' equity	$ 11,805	$ 11,756

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	43,139,000	42,967,000
Common stock, shares outstanding	43,139,000	42,967,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Net revenue
Total net revenue	$ 3,520	$ 4,208
Cost of net revenue	1,354	1,601
Gross profit	2,166	2,607
Operating expenses
Research and development	1,153	1,051
Selling, general and administrative	972	989
Total operating expenses	2,125	2,040
Income from operations	41	567
Interest expense	(54)	(221)
Other income, net	23	3
Income before income taxes	10	349
Income tax provision		1
Net and comprehensive income	$ 10	$ 348
Net income per share
Basic	$ 0	$ 0.04
Diluted	$ 0	$ 0.04
Shares used in computing net income per share
Basic	43,068	8,130
Diluted	45,412	8,347
Product [Member]
Net revenue
Total net revenue	$ 3,386	$ 3,704
Royalty And Other [Member]
Net revenue
Total net revenue	$ 134	$ 504

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2017	$ 7,346	$ 8	$ 232,026	$ (224,688)
Beginning Balance, shares at Dec. 31, 2017		8,068
Cumulative effect of accounting change	230			230
Issuance costs for the sale of common stock	(12)		(12)
Issuance of common stock for release of awards	(38)		(38)
Issuance of common stock for release of awards, shares		103
Stock-based compensation	93		93
Net income	348			348
Ending Balance at Mar. 31, 2018	7,967	$ 8	232,069	(224,110)
Ending Balance, shares at Mar. 31, 2018		8,171
Beginning Balance at Dec. 31, 2018	$ 7,157	$ 43	242,981	(235,867)
Beginning Balance, shares at Dec. 31, 2018	42,967	42,967
Issuance of common stock for release of awards	$ (1)		(1)
Issuance of common stock for release of awards, shares		172
Stock-based compensation	(4)		(4)
Net income	10			10
Ending Balance at Mar. 31, 2019	$ 7,162	$ 43	$ 242,976	$ (235,857)
Ending Balance, shares at Mar. 31, 2019	43,139	43,139

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net income	$ 10	$ 348
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization	72	169
Stock-based compensation	(4)	94
Amortization of intangible assets		27
Amortization of debt issuance costs		12
Accrued interest	54	209
Other	(2)
Changes in assets and liabilities
Accounts receivable	(549)	406
Inventories	246	(134)
Prepaid expenses and other assets	(248)	93
Accounts payable	(21)	63
Deferred revenue and other liabilities	(284)	(1,604)
Net cash used in operating activities	(726)	(317)
Cash flows from investing activities:
Purchases of property and equipment	(48)
Purchases of marketable securities	(1,564)
Net cash used in investing activities	(1,612)
Cash flows from financing activities:
Issuance costs for sale of common stock		(12)
Taxes paid to net share settle equity awards	(1)	(38)
Net cash used in financing activities	(1)	(50)
Net decrease in cash and cash equivalents	(2,339)	(367)
Cash and cash equivalents at beginning of period	7,104	3,868
Cash and cash equivalents at end of period	4,765	3,501
Supplemental disclosure:
Issuance of convertible notes in settlement of accrued interest	$ 78	$ 463

The Company and Summary of Sign

The Company and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
The Company and Summary of Significant Accounting Policies	Note 1. The Company and Summary of Significant Accounting Policies MoSys, Inc. (the “Company”) was incorporated in California in September 1991 and reincorporated in September 2000 in Delaware. The Company’s strategy and primary business objective is to be an IP-rich The accompanying condensed consolidated financial statements of the Company have been prepared without audit. The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP) have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019 or for any other future period. Basis of Presentation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on December 31 of each calendar year. Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates. Cash Equivalents and Investments The Company invests its excess cash in money market accounts, certificates of deposit, commercial paper, corporate debt, government-sponsored enterprise bonds and municipal bonds and considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Investments with original maturities greater than three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. Management generally determines the appropriate classification of securities at the time of purchase. All securities are classified as available-for-sale. available-for-sale Fair Value Measurements The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: Level 1— Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Level 2— Pricing is provided by third party sources of market information obtained through the Company’s investment advisors, rather than models. The Company does not adjust for, or apply, any additional assumptions or estimates to the pricing information it receives from advisors. The Company’s Level 2 securities may include cash equivalents and available-for-sale Level 3— Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment are used to measure fair value. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 investments and other financial instruments involves the most management judgment and subjectivity. Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure that its trade receivables balances are not overstated due to uncollectibility. The Company performs ongoing customer credit evaluations within the context of the industry in which it operates and generally does not require collateral from its customers. A specific allowance of up to 100% of the invoice value is provided for any problematic customer balances. Delinquent account balances are written off after management has determined that the likelihood of collection is remote. The Company grants credit only to customers deemed creditworthy in the judgment of management. There was no allowance for doubtful accounts receivable at either March 31, 2019 or December 31, 2018. Inventories The Company values its inventories at the lower of cost, which approximates actual cost on a first-in, first-out Revenue Recognition The Company generates revenue primarily from sales of IC products and licensing of its IP. Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. IC products Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company’s contracts have a single performance obligation to transfer products. Accordingly, the Company recognizes revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. The Company sells its products both directly to customers and through distributors generally under agreements with payment terms typically less than 60 days. The Company may record an estimated allowance, at the time of shipment, for future returns and other charges against revenue consistent with the terms of sale. Royalty and other The Company’s licensing contracts typically provide for royalties based on the licensee’s use of the Company’s memory technology in its currently shipping commercial products. The Company estimates its royalty revenue in the calendar quarter in which the licensee uses the licensed technology. Payments are generally received in the subsequent quarter. Contract liabilities – deferred revenue The Company’s contract liabilities consist of advance customer payments and deferred revenue. The Company classifies advance customer payments and deferred revenue as current or non-current During the three months ended March 31, 2019, the Company recognized revenue of $0.2 million that had been included in deferred revenue at December 31, 2018. See Note 5 for disaggregation of revenue by geography. Cost of Net Revenue Cost of net revenue consists primarily of direct and indirect costs of IC product sales and engineering personnel costs directly related to maintenance and support services specified in licensing agreements. Maintenance and support typically include engineering support to assist in the commencement of production of a licensee’s products. Goodwill The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized. The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. As the Company uses the market approach to determine the step one fair value, the price of its common stock is an important component of the fair value calculation. If the Company’s stock price continues to experience significant price and volume fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods. The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not Warrants As of March 31, 2019 and December 31, 2018, the company had the following outstanding warrants to purchase common stock: Warrant type Number of shares Exercise Price Expiration date Pre-funded 2,310,776 $ 0.001 None Common stock 662,500 $ 2.35 January 2023 Common stock 36,910,809 $ 0.30 October 2023 Per Share Amounts Basic net income per share is computed by dividing net income for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options, vesting of stock awards and shares issuable in conjunction with our convertible debt. The following table sets forth the computation of basic and diluted net income per share for the periods indicated (in thousands, except per share amounts): Three months ended March 31, 2019 2018 Numerator: Net Income $ 10 $ 348 Denominator: Add: weighted-average common shares outstanding 43,068 8,130 Total shares: basic 43,068 8,130 Add: weighted-average stock options outstanding — 63 Add: weighted-average unvested restricted stock units 46 154 Add: weighted-average shares issuable on conversion of warrants 2,298 — Total shares: diluted 45,412 8,347 Net income per share: Basic $ 0.00 $ 0.04 Diluted $ 0.00 $ 0.04 The following table sets forth securities outstanding which were excluded from the computation of diluted net income per share as their inclusion would be anti-dilutive (in thousands): March 31, 2019 2018 Options outstanding to purchase common stock 1,633 186 Convertible debt 4,809 2,272 Outstanding warrants 37,573 — Total 44,015 2,458 Debt Issuance Costs Debt issuance costs are capitalized and amortized to interest expense using the effective interest method. Unamortized debt issuance costs are presented in the condensed consolidated balance sheets as a direct deduction from the carrying amount of the related debt liability and accounted for as debt discounts. Recently Adopted Accounting Standards In 2016, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) No. 2016-02 2018-10, Codification Improvements to Topic 842 2018-11, Leases (Topic 842): Targeted Improvements No. 2018-11 No. 2016-02 2019-01, Leases (Topic 842): Codification Improvements, No. 2016-02 No. 2016-02, No. 2018-11. non-lease In 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718), Improvements to Employee Share-based Payment Accounting No. 2016-09 No. 2016-09 No. 2016-09 No. 2016-09,

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 2: Fair Value of Financial Instruments The estimated fair values of financial instruments outstanding were (in thousands): March 31, 2019 Cost Unrealized Unrealized Fair Cash and cash equivalents $ 4,765 $ — $ — $ 4,765 Short-term investments 1,564 — — 1,564 $ 6,329 $ — $ — $ 6,329 December 31, 2018 Cost Unrealized Unrealized Fair Cash and cash equivalents $ 7,104 $ — $ — $ 7,104 The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands): March 31, 2019 Fair Value Level 1 Level 2 Level 3 Money market funds $ 3,233 $ 3,233 $ — $ — Corporate notes and commercial paper $ 1,564 $ — $ 1,564 $ — December 31, 2018 Fair Value Level 1 Level 2 Level 3 Money market funds $ 632 $ 632 $ — $ — There were no transfers in or out of Level 1 and Level 2 securities during the three months ended March 31, 2019 or 2018.

Balance Sheet Detail

Balance Sheet Detail	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Detail	Note 3. Balance Sheet Detail March 31, December 31, (in thousands) Inventories: Work-in-process $ 474 $ 548 Finished goods 428 600 $ 902 $ 1,148 Amortization expense for an identifiable intangible asset, which was fully amortized during 2018, has been included in research and development expense in the condensed consolidated statement of operations and comprehensive income.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 4. Commitments and Contingencies Indemnification In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No material amounts were reflected in the Company’s condensed consolidated financial statements for the three months ended March 31, 2019 or 2018 related to these indemnifications. The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any material payments related to these indemnification agreements. Legal Matters The Company is not a party to any legal proceeding that the Company believes is likely to have a material adverse effect on its condensed consolidated financial position or results of operations. From time to time the Company may be subject to legal proceedings and claims in the ordinary course of business. These claims, even if not meritorious, could result in the expenditure of significant financial resources and diversion of management efforts.

Business Segments, Concentratio

Business Segments, Concentration of Credit Risk and Significant Customers	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Business Segments, Concentration of Credit Risk and Significant Customers	Note 5. Business Segments, Concentration of Credit Risk and Significant Customers The Company operates in one business segment and uses one measurement of profitability for its business. Net revenue is attributed to the United States and to all foreign countries based on the geographical location of the customer. The Company recognized revenue from shipment of product and licensing of its technologies to customers by geographical location as follows (in thousands): Three Months Ended 2019 2018 North America $ 2,487 $ 3,357 Japan 906 714 Taiwan 74 83 Rest of world 53 54 Total net revenue $ 3,520 $ 4,208 Customers who accounted for at least 10% of total net revenue were: Three Months Ended 2019 2018 Customer A 26 % 17 % Customer B 23 % 34 % Customer C 15 % 24 % Customer D 14 % * % Customer E 13 % 10 % * Represents less than 10% Three customers accounted for 94% of accounts receivable at March 31, 2019. Three customers accounted for 63% of accounts receivable at December 31, 2018.

Income Tax Provision

Income Tax Provision	3 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income Tax Provision	Note 6. Income Tax Provision The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. The Company files U.S. federal and state and foreign income tax returns in jurisdictions with varying statutes of limitations. All tax returns from 2013 to 2017 may be subject to examination by the Internal Revenue Service, California and other states. Returns filed in foreign jurisdictions may be subject to examination for the years 2009 to 2017. As of March 31, 2019, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Note 7. Stock-Based Compensation The expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant-date fair value. The unamortized compensation cost, as of March 31, 2019, was $0.5 million related to stock options and is expected to be recognized as expense over a weighted-average period of approximately 3.0 years. The expense related to restricted stock units (RSUs) is recognized over a three-to-four For the three months ended March 31, 2019 and 2018, there were no excess tax benefits associated with the exercise of stock options due to the Company’s historical loss positions. Valuation Assumptions The fair value of the Company’s stock options granted during the three months ended March 31, 2019 and 2018 was estimated on the grant dates using the Black-Scholes valuation option-pricing model with the following assumptions: Three Months Ended 2019 2018 Risk-free interest rate 2.5 % 2.2 % Volatility 128.4 % 109.5 % Expected life (years) 3 - 5 4.0 Dividend yield — % — % The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. The expected volatility was based on the historical volatility of the Company’s stock price over the expected term of the options. The expected term of options granted was derived from historical data based on employee exercises and post-vesting Prior to January 1, 2019, the stock-based Stock-based No. 2016-09 Common Stock Options and Restricted Stock A summary of option and RSU activity under the Company’s Amended and Restated 2010 Equity Incentive Plan (the Plan) is presented below (in thousands, except exercise price): Options outstanding Shares Number of Weighted Balance at January 1, 2019 4,007 337 $ 4.19 Additional shares authorized under the Plan 50 — — RSUs granted (2,028 ) — — RSUs cancelled and returned to the Plan 11 — — Options granted (1,297 ) 1,297 $ 0.20 Options cancelled and returned to the Plan 1 (1 ) $ 7.20 Balance at March 31, 2019 744 1,633 $ 1.02 A summary of RSU activity under the Plan is presented below (in thousands, except for fair value): Number of Weighted Grant-Date Non-vested 272 $ 1.23 Granted 2,028 $ 0.20 Vested (167 ) $ 1.48 Cancelled (11 ) $ 1.26 Non-vested 2,122 $ 0.23 The total intrinsic value of the RSUs outstanding as of March 31, 2019 was $0.4 million. The following table summarizes significant ranges of outstanding and exercisable options as of March 31, 2019 (in thousands, except contractual life and exercise price): Options Outstanding Options Exercisable Range of Exercise Price Number Weighted (in Years) Weighted Number Weighted Aggregate $0.18 - $0.74 1,297 2.80 $ 0.20 30 $ 0.20 $ — $0.75 - $1.27 160 4.55 $ 0.75 53 $ 0.75 $ — $1.28 - $7.19 51 5.15 $ 2.09 23 $ 2.93 $ — $7.20 - $20.49 106 7.04 $ 7.20 92 $ 7.20 $ — $20.50 - $46.20 19 5.94 $ 21.53 19 $ 21.53 $ — $0.18 - $46.20 1,633 5.52 $ 1.02 217 $ 5.46 $ — There were no stock options exercised during the three months ended March 31, 2019 or 2018.

Convertible Notes

Convertible Notes	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Convertible Notes	Note 8. Convertible Notes In March 2016, the Company entered into a 10% Senior Secured Convertible Note Purchase Agreement (the “Purchase Agreement”) with the purchasers of $8,000,000 principal amount of 10% Senior Secured Convertible Notes due August 15, 2018 (the “Notes”), at par, in a private placement transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended. Pursuant to amendments to the Notes and related documents in February and October 2018, the interest rate was reduced to 8%, the maturity date of the Notes was extended to August 15, 2023, and the optional conversion price was reduced from $8.50 of Note principal per share of common stock to $0.5717 of Note principal per share of common stock. The conversion price is subject to adjustment upon certain events, such as stock splits, reverse stock splits, stock dividends and similar kinds of transactions, as set forth in the Purchase Agreement. Pursuant to a security agreement entered into by the Company, the Notes are secured by a security interest in all of the assets of the Company. Accrued interest is payable semi-annually in cash or in kind through the issuance of identical new Notes, or with a combination of the two, at the Company’s option. The Notes are noncallable and nonredeemable by the Company. The Notes are redeemable at the election of the holders if the Company experiences a fundamental change (as defined in the Notes), which generally would occur in the event (i) any person acquires beneficial ownership of shares of common stock of the Company entitling such person to exercise at least 40% of the total voting power of all of the shares of capital stock of the Company entitled to vote generally in elections of directors, (ii) an acquisition of the Company by another person through a merger or consolidation, or the sale, transfer or lease of all or substantially all of the Company’s assets, or (iii) the Company’s current directors cease to constitute a majority of the board of directors of the Company within a 12-month No Note holder shall be entitled to convert such holder’s Notes if effective upon the applicable conversion date (i) the holder would have beneficial ownership of more than 19.9% of the voting capital stock of the Company as determined in accordance with Rule 13d-3 The Notes restrict the ability of the Company to incur any indebtedness for borrowed money, unless such indebtedness by its terms is expressly subordinated to the Notes in right of payment and to the security interest of the Note holder(s) in respect to the priority and enforcement of any security interest in property of the Company securing such new debt; provided that the Note holder(s) security interest and cash payment rights under the Notes shall be subordinate to a maximum of $5,000,000 of indebtedness for a secured accounts receivable line of credit facility provided to the Company by a bank or institutional lender; and, provided further, that in no event may the amount of indebtedness to which the security interest of the Note holder(s) is subordinated exceed the outstanding balance of accounts receivable less than 90 days old for which the Company has not recorded an allowance for doubtful accounts pledged under such credit facility. The Notes define an event of default generally as any failure by the Company to pay an amount owed under the Notes when due (subject to cure periods), a default with respect to other indebtedness of the Company resulting in acceleration of such indebtedness, the commencement of bankruptcy or insolvency proceedings, or the cessation of business. If an event of default occurs under the Notes, the holder(s) of a majority-in-interest The Company incurred debt issuance costs of approximately $0.1 million, which were recorded as a debt discount and are being amortized to interest expense over the repayment period for the original loan using the effective interest rate method. The interest expense related to the debt discount during the three months ended March 31, 2019 and 2018 was approximately zero and $12,000, respectively. In accordance with the October 2018 amendment to the Notes, the Company used $7.4 million of the proceeds from a public offering of securities effected in October 2018 to repay a portion of the Notes. As of March 31, 2019, the outstanding convertible notes payable of $2.7 million were due in August 2023. In February 2019, a semi-annual interest payment of approximately $78,000 was paid in-kind with the issuance of an additional note (the Interest Note) to the Purchasers. The Interest Note has terms identical to the Notes. As of March 31, 2019, the Notes and Interest Note could be converted into a maximum of 4,808,626 shares of common stock at $0.5717 per share, excluding the effects of future payments of interest in-kind

Leases

Leases	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Leases	Note 9. Leases Effective January 1, 2019, the Company adopted ASU No. 2016-02, No. 2016-02. non-lease right-to-use No. 2016-02 The Company identified only one lease to be accounted for under ASU No. 2016-02, right-to-use Our future minimum payments under our facility operating lease as of March 31, 2019 are listed in the table below (in thousands). Year Operating Lease 2019 $ 164 2020 187 Total future lease payments 351 Less: imputed interest (39 ) Present value of lease liabilities $ 312 Supplemental cash flow information related to the operating lease was as follows (in thousands): Three months ended Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for lease $ 54

The Company and Summary of Si_2

The Company and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on December 31 of each calendar year.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates.
Cash Equivalents and Investments	Cash Equivalents and Investments The Company invests its excess cash in money market accounts, certificates of deposit, commercial paper, corporate debt, government-sponsored enterprise bonds and municipal bonds and considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Investments with original maturities greater than three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. Management generally determines the appropriate classification of securities at the time of purchase. All securities are classified as available-for-sale. available-for-sale
Fair Value Measurements	Fair Value Measurements The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: Level 1— Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Level 2— Pricing is provided by third party sources of market information obtained through the Company’s investment advisors, rather than models. The Company does not adjust for, or apply, any additional assumptions or estimates to the pricing information it receives from advisors. The Company’s Level 2 securities may include cash equivalents and available-for-sale Level 3— Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment are used to measure fair value. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 investments and other financial instruments involves the most management judgment and subjectivity.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure that its trade receivables balances are not overstated due to uncollectibility. The Company performs ongoing customer credit evaluations within the context of the industry in which it operates and generally does not require collateral from its customers. A specific allowance of up to 100% of the invoice value is provided for any problematic customer balances. Delinquent account balances are written off after management has determined that the likelihood of collection is remote. The Company grants credit only to customers deemed creditworthy in the judgment of management. There was no allowance for doubtful accounts receivable at either March 31, 2019 or December 31, 2018.
Inventories	Inventories The Company values its inventories at the lower of cost, which approximates actual cost on a first-in, first-out
Revenue Recognition	Revenue Recognition The Company generates revenue primarily from sales of IC products and licensing of its IP. Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. IC products Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company’s contracts have a single performance obligation to transfer products. Accordingly, the Company recognizes revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. The Company sells its products both directly to customers and through distributors generally under agreements with payment terms typically less than 60 days. The Company may record an estimated allowance, at the time of shipment, for future returns and other charges against revenue consistent with the terms of sale. Royalty and other The Company’s licensing contracts typically provide for royalties based on the licensee’s use of the Company’s memory technology in its currently shipping commercial products. The Company estimates its royalty revenue in the calendar quarter in which the licensee uses the licensed technology. Payments are generally received in the subsequent quarter. Contract liabilities – deferred revenue The Company’s contract liabilities consist of advance customer payments and deferred revenue. The Company classifies advance customer payments and deferred revenue as current or non-current During the three months ended March 31, 2019, the Company recognized revenue of $0.2 million that had been included in deferred revenue at December 31, 2018. See Note 5 for disaggregation of revenue by geography.
Cost of Net Revenue	Cost of Net Revenue Cost of net revenue consists primarily of direct and indirect costs of IC product sales and engineering personnel costs directly related to maintenance and support services specified in licensing agreements. Maintenance and support typically include engineering support to assist in the commencement of production of a licensee’s products.
Goodwill	Goodwill The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized. The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. As the Company uses the market approach to determine the step one fair value, the price of its common stock is an important component of the fair value calculation. If the Company’s stock price continues to experience significant price and volume fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods. The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not
Warrants	Warrants As of March 31, 2019 and December 31, 2018, the company had the following outstanding warrants to purchase common stock: Warrant type Number of shares Exercise Price Expiration date Pre-funded 2,310,776 $ 0.001 None Common stock 662,500 $ 2.35 January 2023 Common stock 36,910,809 $ 0.30 October 2023
Per Share Amounts	Per Share Amounts Basic net income per share is computed by dividing net income for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options, vesting of stock awards and shares issuable in conjunction with our convertible debt. The following table sets forth the computation of basic and diluted net income per share for the periods indicated (in thousands, except per share amounts): Three months ended March 31, 2019 2018 Numerator: Net Income $ 10 $ 348 Denominator: Add: weighted-average common shares outstanding 43,068 8,130 Total shares: basic 43,068 8,130 Add: weighted-average stock options outstanding — 63 Add: weighted-average unvested restricted stock units 46 154 Add: weighted-average shares issuable on conversion of warrants 2,298 — Total shares: diluted 45,412 8,347 Net income per share: Basic $ 0.00 $ 0.04 Diluted $ 0.00 $ 0.04 The following table sets forth securities outstanding which were excluded from the computation of diluted net income per share as their inclusion would be anti-dilutive (in thousands): March 31, 2019 2018 Options outstanding to purchase common stock 1,633 186 Convertible debt 4,809 2,272 Outstanding warrants 37,573 — Total 44,015 2,458
Debt Issuance Costs	Debt Issuance Costs Debt issuance costs are capitalized and amortized to interest expense using the effective interest method. Unamortized debt issuance costs are presented in the condensed consolidated balance sheets as a direct deduction from the carrying amount of the related debt liability and accounted for as debt discounts.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In 2016, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) No. 2016-02 2018-10, Codification Improvements to Topic 842 2018-11, Leases (Topic 842): Targeted Improvements No. 2018-11 No. 2016-02 2019-01, Leases (Topic 842): Codification Improvements, No. 2016-02 No. 2016-02, No. 2018-11. non-lease In 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718), Improvements to Employee Share-based Payment Accounting No. 2016-09 No. 2016-09 No. 2016-09 No. 2016-09,

The Company and Summary of Si_3

The Company and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Schedule of outstanding warrants to purchase of common stock	As of March 31, 2019 and December 31, 2018, the company had the following outstanding warrants to purchase common stock: Warrant type Number of shares Exercise Price Expiration date Pre-funded 2,310,776 $ 0.001 None Common stock 662,500 $ 2.35 January 2023 Common stock 36,910,809 $ 0.30 October 2023
Summary of Computation of Basic and Diluted Net Income (Loss) Per Share	The following table sets forth the computation of basic and diluted net income per share for the periods indicated (in thousands, except per share amounts): Three months ended March 31, 2019 2018 Numerator: Net Income $ 10 $ 348 Denominator: Add: weighted-average common shares outstanding 43,068 8,130 Total shares: basic 43,068 8,130 Add: weighted-average stock options outstanding — 63 Add: weighted-average unvested restricted stock units 46 154 Add: weighted-average shares issuable on conversion of warrants 2,298 — Total shares: diluted 45,412 8,347 Net income per share: Basic $ 0.00 $ 0.04 Diluted $ 0.00 $ 0.04
Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share	The following table sets forth securities outstanding which were excluded from the computation of diluted net income per share as their inclusion would be anti-dilutive (in thousands): March 31, 2019 2018 Options outstanding to purchase common stock 1,633 186 Convertible debt 4,809 2,272 Outstanding warrants 37,573 — Total 44,015 2,458

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of estimated fair values of financial instruments outstanding	The estimated fair values of financial instruments outstanding were (in thousands): March 31, 2019 Cost Unrealized Unrealized Fair Cash and cash equivalents $ 4,765 $ — $ — $ 4,765 Short-term investments 1,564 — — 1,564 $ 6,329 $ — $ — $ 6,329 December 31, 2018 Cost Unrealized Unrealized Fair Cash and cash equivalents $ 7,104 $ — $ — $ 7,104
Schedule of fair value hierarchy for financial assets (cash equivalents and investments)	The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands): March 31, 2019 Fair Value Level 1 Level 2 Level 3 Money market funds $ 3,233 $ 3,233 $ — $ — Corporate notes and commercial paper $ 1,564 $ — $ 1,564 $ — December 31, 2018 Fair Value Level 1 Level 2 Level 3 Money market funds $ 632 $ 632 $ — $ —

Balance Sheet Detail (Tables)

Balance Sheet Detail (Tables)	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of inventory	March 31, December 31, (in thousands) Inventories: Work-in-process $ 474 $ 548 Finished goods 428 600 $ 902 $ 1,148

Business Segments, Concentrat_2

Business Segments, Concentration of Credit Risk and Significant Customers (Tables)	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Schedule of revenue from shipment of product and licensing of its technologies to customers by geographical location	The Company recognized revenue from shipment of product and licensing of its technologies to customers by geographical location as follows (in thousands): Three Months Ended 2019 2018 North America $ 2,487 $ 3,357 Japan 906 714 Taiwan 74 83 Rest of world 53 54 Total net revenue $ 3,520 $ 4,208
Schedule of customers who accounted for at least 10% of total net revenue	Customers who accounted for at least 10% of total net revenue were: Three Months Ended 2019 2018 Customer A 26 % 17 % Customer B 23 % 34 % Customer C 15 % 24 % Customer D 14 % * % Customer E 13 % 10 % * Represents less than 10%

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of assumptions used in estimation of fair value of the share-based payment awards on the grant date	The fair value of the Company’s stock options granted during the three months ended March 31, 2019 and 2018 was estimated on the grant dates using the Black-Scholes valuation option-pricing model with the following assumptions: Three Months Ended 2019 2018 Risk-free interest rate 2.5 % 2.2 % Volatility 128.4 % 109.5 % Expected life (years) 3 - 5 4.0 Dividend yield — % — %
Summary of option and RSU activity under Amended and Restated 2000 Stock Option and Equity Incentive Plan and Amended and Restated 2010 Equity Incentive Plan	A summary of option and RSU activity under the Company’s Amended and Restated 2010 Equity Incentive Plan (the Plan) is presented below (in thousands, except exercise price): Options outstanding Shares Number of Weighted Balance at January 1, 2019 4,007 337 $ 4.19 Additional shares authorized under the Plan 50 — — RSUs granted (2,028 ) — — RSUs cancelled and returned to the Plan 11 — — Options granted (1,297 ) 1,297 $ 0.20 Options cancelled and returned to the Plan 1 (1 ) $ 7.20 Balance at March 31, 2019 744 1,633 $ 1.02
Summary of RSU activity under the Plan	A summary of RSU activity under the Plan is presented below (in thousands, except for fair value): Number of Weighted Grant-Date Non-vested 272 $ 1.23 Granted 2,028 $ 0.20 Vested (167 ) $ 1.48 Cancelled (11 ) $ 1.26 Non-vested 2,122 $ 0.23
Summary of significant ranges of outstanding and exercisable options	The following table summarizes significant ranges of outstanding and exercisable options as of March 31, 2019 (in thousands, except contractual life and exercise price): Options Outstanding Options Exercisable Range of Exercise Price Number Weighted (in Years) Weighted Number Weighted Aggregate $0.18 - $0.74 1,297 2.80 $ 0.20 30 $ 0.20 $ — $0.75 - $1.27 160 4.55 $ 0.75 53 $ 0.75 $ — $1.28 - $7.19 51 5.15 $ 2.09 23 $ 2.93 $ — $7.20 - $20.49 106 7.04 $ 7.20 92 $ 7.20 $ — $20.50 - $46.20 19 5.94 $ 21.53 19 $ 21.53 $ — $0.18 - $46.20 1,633 5.52 $ 1.02 217 $ 5.46 $ —

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Schedule of Future Minimum Payments under Facility Operating Lease	Our future minimum payments under our facility operating lease as of March 31, 2019 are listed in the table below (in thousands). Year Operating Lease 2019 $ 164 2020 187 Total future lease payments 351 Less: imputed interest (39 ) Present value of lease liabilities $ 312
Schedule of Supplemental Cash Flow Information Related to Operating lease	Supplemental cash flow information related to the operating lease was as follows (in thousands): Three months ended Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for lease $ 54

The Company and Summary of Si_4

The Company and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Allowance for doubtful accounts receivable	$ 0		$ 0
Maximum specific allowance as percentage of invoice value for problematic customer balances	100.00%
Payment terms	The Company sells its products both directly to customers and through distributors generally under agreements with payment terms typically less than 60 days.
Deferred revenue, revenue recognized	$ 200
Right of use assets and lease liability	$ 297	$ 400

The Company and Summary of Si_5

The Company and Summary of Significant Accounting Policies - Summary of outstanding warrants to purchase common stock (Detail) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Pre Funded Common Stock Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares	2,310,776	2,310,776
Exercise Price	$ 0.001	$ 0.001
Common Stock Warrants One [Member]
Class of Warrant or Right [Line Items]
Number of shares	662,500	662,500
Exercise Price	$ 2.350	$ 2.350
Expiration date	Jan. 30, 2023	Jan. 30, 2023
Common Stock Warrants Two [Member]
Class of Warrant or Right [Line Items]
Number of shares	36,910,809	36,910,809
Exercise Price	$ 0.300	$ 0.300
Expiration date	Oct. 30, 2023	Oct. 30, 2023

The Company and Summary of Si_6

The Company and Summary of Significant Accounting Policies - Summary of Computation of Basic and Diluted Net Income (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Numerator:
Net Income	$ 10	$ 348
Shares used in computing net income (loss) per share
Add: weighted-average common shares outstanding	43,068	8,130
Total shares: basic	43,068	8,130
Total shares: diluted	45,412	8,347
Net income per share:
Basic	$ 0	$ 0.04
Diluted	$ 0	$ 0.04
Stock Option [Member]
Shares used in computing net income (loss) per share
Weighted-average stock options, restricted stock and issuable on conversion of warrants		63
RSU's
Shares used in computing net income (loss) per share
Weighted-average stock options, restricted stock and issuable on conversion of warrants	46	154
Outstanding warrants
Shares used in computing net income (loss) per share
Weighted-average stock options, restricted stock and issuable on conversion of warrants	2,298

The Company and Summary of Si_7

The Company and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	44,015	2,458
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,633	186
Convertible debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,809	2,272
Outstanding warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	37,573

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Estimated Fair Values of Financial Instruments Outstanding (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]
Cost	$ 6,329
Unrealized Gains	0
Unrealized Losses	0
Fair Value	6,329
Cash and Cash Equivalents
Debt Securities, Available-for-sale [Line Items]
Cost	4,765	$ 7,104
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	4,765	$ 7,104
Short-term investments
Debt Securities, Available-for-sale [Line Items]
Cost	1,564
Unrealized Gains	0
Unrealized Losses	0
Fair Value	$ 1,564

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Schedule of fair value hierarchy for financial assets (cash equivalents and investments) (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Money market funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 3,233	$ 632
Corporate notes and commercial paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	1,564
Fair Value, Measurements, Recurring [Member] | Money market funds [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	3,233	$ 632
Fair Value, Measurements, Recurring [Member] | Corporate notes and commercial paper [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 1,564

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Transfer of assets between Level 1 to Level 2	$ 0	$ 0
Transfer of assets between Level 2 to Level 1	0	0
Transfer of liabilities between Level 1 to Level 2	0	0
Transfer of liabilities between Level 2 to Level 1	$ 0	$ 0

Balance Sheet Detail - Schedule

Balance Sheet Detail - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Work-in-process	$ 474	$ 548
Finished goods	428	600
Total	$ 902	$ 1,148

Business Segments, Concentrat_3

Business Segments, Concentration of Credit Risk and Significant Customers - Additional Information (Detail)	3 Months Ended	12 Months Ended
	Mar. 31, 2019CustomerSegment	Dec. 31, 2018Customer
Business Segments
Number of business segments | Segment	1
Number of measurements of profitability	1
Accounts Receivable | Major customers | Credit Concentration
Business Segments
Percentage of concentration risk	94.00%	63.00%
Number of customer | Customer	3	3

Business Segments, Concentrat_4

Business Segments, Concentration of Credit Risk and Significant Customers - Schedule of Revenue from Shipment of Product and Licensing of its Technologies to Customers by Geographical Location (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Business Segments
Total net revenue	$ 3,520	$ 4,208
North America [Member]
Business Segments
Total net revenue	2,487	3,357
Japan [Member]
Business Segments
Total net revenue	906	714
Taiwan [Member]
Business Segments
Total net revenue	74	83
Rest of world [Member]
Business Segments
Total net revenue	$ 53	$ 54

Business Segments, Concentrat_5

Business Segments, Concentration of Credit Risk and Significant Customers - Schedule of Customers Who Accounted for at Least 10% of Total Net Revenue (Detail) - Net Revenues - Customer Concentration	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Customer A
Significant Customers
Percentage of concentration risk	26.00%	17.00%
Customer B
Significant Customers
Percentage of concentration risk	23.00%	34.00%
Customer C
Significant Customers
Percentage of concentration risk	15.00%	24.00%
Customer D
Significant Customers
Percentage of concentration risk	14.00%		[1]
Customer E
Significant Customers
Percentage of concentration risk	13.00%	10.00%
[1]	Represents less than 10%

Income Tax Provision - Addition

Income Tax Provision - Additional Information (Detail)	Mar. 31, 2019USD ($)
Income Tax Disclosure [Abstract]
Unrecognized tax benefits recorded as liability	$ 0

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unamortized compensation cost, net of expected forfeitures	$ 500,000
Weighted average expected period over which the expense is to be recognized	3 years
Tax benefits associated with exercise of stock options	$ 0	$ 0
RSU's
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average expected period over which the expense is to be recognized	3 months 18 days
Unamortized compensation cost, net of expected forfeitures	$ 400,000
Stock options exercised	0	0
RSU's | Equity Incentive Plan 2010
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total intrinsic value of the restricted stock units outstanding	$ 400,000
RSU's | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense, recognition period	3 years
RSU's | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense, recognition period	4 years

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Assumptions Used in Estimation of Fair Value of the Share-based Payment Awards on the Grant Date (Detail) - Options	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	2.50%	2.20%
Volatility	128.40%	109.50%
Expected life (years)		4 years
Dividend yield	0.00%	0.00%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (years)	3 years
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (years)	5 years

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Option and RSU Activity (Detail) - Equity Incentive Plan 2010 shares in Thousands	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Number of shares
Balance at the beginning of the year (in shares)	4,007
Options granted (in shares)	(1,297)
Options cancelled and returned to Plan (in shares)	1
Balance at the end of the period (in shares)	744
Number of shares
Balance at the beginning of the year (in shares)	337
Options granted (in shares)	1,297
Options cancelled and returned to Plan (in shares)	(1)
Balance at the end of the period (in shares)	1,633
Weighted Average Exercise Prices
Weighted-average exercise price (in dollars per share) | $ / shares	$ 4.19
Options granted (in dollars per share) | $ / shares	0.20
Options cancelled and returned to Plan (in dollars per share) | $ / shares	7.20
Weighted-average exercise price (in dollars per share) | $ / shares	$ 1.02
RSU's
Number of shares
RSUs granted (in shares)	(2,028)
RSUs cancelled and returned to Plan (in shares)	11
Number of shares
RSUs granted (in shares)	2,028
RSUs cancelled and returned to Plan (in shares)	11
Options
Number of shares
Additional shares authorized under the Plan	50
Number of shares
Additional shares authorized under the Plan	50

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of RSU Activity (Detail) - Equity Incentive Plan 2010 - RSU's shares in Thousands	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Number of Shares
Non-vested shares at the beginning of the year | shares	272
Granted (in shares) | shares	2,028
Vested (in shares) | shares	(167)
Cancelled (in shares) | shares	(11)
Non-vested shares at the end of the period | shares	2,122
Weighted Average Grant-Date Fair Value
Weighted average grant date fair value | $ / shares	$ 1.23
Granted (in shares) | $ / shares	0.20
Vested (in shares) | $ / shares	1.48
Cancelled (in shares) | $ / shares	1.26
Weighted average grant date fair value | $ / shares	$ 0.23

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Significant Ranges of Outstanding and Exercisable Options (Detail) - Options $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
$0.18 - $0.74
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	$ 0.18
Upper range limit (in dollars per share)	$ 0.74
Number Outstanding (in shares | shares	1,297
Weighted Average Remaining Contractual Life	2 years 9 months 18 days
Weighted Average Exercise Price (in dollars per share)	$ 0.20
Number Exercisable (in shares | shares	30
Weighted Average Exercise Price (in dollars per share)	$ 0.20
Aggregate Intrinsic value | $	$ 0
$0.75 - $1.27
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	$ 0.75
Upper range limit (in dollars per share)	$ 1.27
Number Outstanding (in shares | shares	160
Weighted Average Remaining Contractual Life	4 years 6 months 18 days
Weighted Average Exercise Price (in dollars per share)	$ 0.75
Number Exercisable (in shares | shares	53
Weighted Average Exercise Price (in dollars per share)	$ 0.75
Aggregate Intrinsic value | $	$ 0
$1.28 - $7.19
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	$ 1.28
Upper range limit (in dollars per share)	$ 7.19
Number Outstanding (in shares | shares	51
Weighted Average Remaining Contractual Life	5 years 1 month 24 days
Weighted Average Exercise Price (in dollars per share)	$ 2.09
Number Exercisable (in shares | shares	23
Weighted Average Exercise Price (in dollars per share)	$ 2.93
Aggregate Intrinsic value | $	$ 0
$7.20 - $20.49
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	$ 7.20
Upper range limit (in dollars per share)	$ 20.49
Number Outstanding (in shares | shares	106
Weighted Average Remaining Contractual Life	7 years 14 days
Weighted Average Exercise Price (in dollars per share)	$ 7.20
Number Exercisable (in shares | shares	92
Weighted Average Exercise Price (in dollars per share)	$ 7.20
Aggregate Intrinsic value | $	$ 0
$20.50 - $46.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	$ 20.50
Upper range limit (in dollars per share)	$ 46.20
Number Outstanding (in shares | shares	19
Weighted Average Remaining Contractual Life	5 years 11 months 8 days
Weighted Average Exercise Price (in dollars per share)	$ 21.53
Number Exercisable (in shares | shares	19
Weighted Average Exercise Price (in dollars per share)	$ 21.53
Aggregate Intrinsic value | $	$ 0
$0.18 - $46.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	$ 0.18
Upper range limit (in dollars per share)	$ 46.20
Number Outstanding (in shares | shares	1,633
Weighted Average Remaining Contractual Life	5 years 6 months 7 days
Weighted Average Exercise Price (in dollars per share)	$ 1.02
Number Exercisable (in shares | shares	217
Weighted Average Exercise Price (in dollars per share)	$ 5.46
Aggregate Intrinsic value | $	$ 0

Convertible Notes - Additional

Convertible Notes - Additional Information (Detail) - USD ($)	Feb. 18, 2018	Feb. 17, 2018	Feb. 28, 2019	Oct. 31, 2018	Mar. 31, 2016	Mar. 31, 2019	Mar. 31, 2018
Debt Instrument [Line Items]
Stated interest rate						8.00%
Interest expense						$ 54,000	$ 221,000
Senior Secured Convertible Notes due August 15 2018
Debt Instrument [Line Items]
Principal amount					$ 8,000,000
Stated interest rate				8.00%	10.00%
Minimum ownership percentage triggering event for redemption of notes					40.00%
Redemption purchase price	100.00%	120.00%
Maximum amount of indebtedness subordinated by security interest and cash payment rights under debt instruments					$ 5,000,000
Payment on principle amount of note				$ 7,400,000
Senior Secured Convertible Notes due August 15 2018 | Contractual obligations and other termination costs
Debt Instrument [Line Items]
Debt issuance costs					$ 100,000
Interest expense						0	$ 12,000
Senior Secured Convertible Notes due August 15 2018 | Minimum
Debt Instrument [Line Items]
Percentage of beneficial ownership if effective upon conversion date of debt instrument					19.90%
Senior Secured Convertible Notes due August 15 2018 | Maximum
Debt Instrument [Line Items]
Period for outstanding balance of accounts receivable has not recorded an allowance for doubtful accounts					90 days
Senior Secured Convertible Notes due August 15, 2023
Debt Instrument [Line Items]
Conversion price				$ 0.5717	$ 8.50
Outstanding Notes payable						$ 2,700,000
Interest Note
Debt Instrument [Line Items]
Conversion price						$ 0.5717
Semi-annual interest payments			$ 78,000
Number of shares issuable if notes converted to shares of common stock						4,808,626
Beneficial ownership ceiling						9.90%

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Leases [Abstract]
Right-of-use lease asset	$ 297	$ 400
Short-term lease liability	197	200
Long-term lease liability	115	$ 200	$ 17
Operating leases expense	$ 100
Interest rate	8.00%
Operating leases expiration period	2020-10

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Payments under Facility Operating Lease (Detail) $ in Thousands	Mar. 31, 2019USD ($)
Leases, Operating [Abstract]
2019	$ 164
2020	187
Total future lease payments	351
Less: imputed interest	(39)
Present value of lease liabilities	$ 312

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information Related to Operating lease (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for lease	$ 54